• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

骨髓移植的临床试验。

Clinical trials of bone marrow transplantation.

作者信息

Gale R P

出版信息

Isr J Med Sci. 1986 Mar-Apr;22(3-4):260-3.

PMID:3528045
Abstract

Bone marrow transplantation is increasingly used to treat a spectrum of diseases in man, including immune and genetic disorders, hematological diseases, and cancer. Approximately 11,000 transplants have been performed worldwide since 1970. About two-thirds of these transplants have involved donors, including related and unrelated individuals, and in the remaining third the patient's bone marrow has been used in the form of an autotransplant. In some disorders and under carefully defined circumstances, bone marrow transplantation appears to be the preferred therapy; these diseases include aplastic anemia, acute myelogenous leukemia, acute lymphoblastic leukemia, chronic myelogenous leukemia, and selected immune and genetic disorders. In other circumstances, the value of bone marrow transplantation is less well defined. Diseases in which bone marrow transplantation may be of benefit include Hodgkin's and non-Hodgkin's lymphoma, other cancers, thalassemia, hemoglobinopathies, genetic disorders, and possibly multiple myeloma. It has been difficult to precisely identify the role of bone marrow transplantation in many of these diseases. Prospective randomized controlled clinical trials have sometimes shown an advantage for bone marrow transplantation, but in most circumstances a benefit is as yet unproven. In the U.S. the annual incidence of individuals with diseases in which bone marrow transplantation is thought to be of proven benefit is approximately 5,400, and an additional 15,000 individuals annually have diseases in which bone marrow transplantation is thought to be of possible benefit. This study reviews data available from both controlled and uncontrolled clinical trials indicating the potential role of bone marrow transplantation in the treatment of human diseases.

摘要

骨髓移植越来越多地用于治疗人类的一系列疾病,包括免疫和遗传疾病、血液系统疾病及癌症。自1970年以来,全球已进行了约11000例移植手术。其中约三分之二的移植涉及供体,包括亲属和非亲属个体,其余三分之一则采用患者自身骨髓进行自体移植。在某些疾病以及精心界定的情况下,骨髓移植似乎是首选疗法;这些疾病包括再生障碍性贫血、急性髓性白血病、急性淋巴细胞白血病、慢性髓性白血病以及某些免疫和遗传疾病。在其他情况下,骨髓移植的价值尚不太明确。可能从骨髓移植中获益的疾病包括霍奇金淋巴瘤和非霍奇金淋巴瘤、其他癌症、地中海贫血、血红蛋白病、遗传疾病,可能还有多发性骨髓瘤。很难精确确定骨髓移植在许多这些疾病中的作用。前瞻性随机对照临床试验有时显示骨髓移植具有优势,但在大多数情况下,其益处尚未得到证实。在美国,每年被认为骨髓移植已被证实有益的疾病患者发病率约为5400人,每年还有另外15000人患有被认为骨髓移植可能有益的疾病。本研究回顾了来自对照和非对照临床试验的现有数据,以表明骨髓移植在治疗人类疾病中的潜在作用。

相似文献

1
Clinical trials of bone marrow transplantation.骨髓移植的临床试验。
Isr J Med Sci. 1986 Mar-Apr;22(3-4):260-3.
2
Allogeneic bone marrow transplantation in the treatment of hematologic diseases.异基因骨髓移植治疗血液病。
Clin Pharm. 1985 Mar-Apr;4(2):149-60.
3
Autologous bone marrow transplantation for leukemia.白血病的自体骨髓移植
Semin Oncol. 1993 Oct;20(5 Suppl 6):40-54.
4
Role of bone marrow transplantation in the treatment of hematologic malignancies and solid tumors: critical review of syngeneic, autologous, and allogeneic transplants.骨髓移植在血液系统恶性肿瘤和实体瘤治疗中的作用:对同基因、自体和异基因移植的批判性综述。
Cancer Treat Rep. 1984 Jan;68(1):145-61.
5
Marrow transplantation: the Seattle experience.
Tokai J Exp Clin Med. 1985 Jun;10(2-3):75-83.
6
Bone marrow transplantation in acute leukaemia.
Clin Haematol. 1986 Aug;15(3):851-72.
7
Bone marrow transplantation in leukemia.
Ann Clin Res. 1981;13(4-5):367-72.
8
Bone marrow transplantation in Canada.加拿大的骨髓移植
Can Med Assoc J. 1980 Jul 5;123(1):19-22.
9
[Indications, technique and risks in bone marrow transplantation in adulthood].[成人骨髓移植的适应症、技术及风险]
Praxis (Bern 1994). 1996 Mar 19;85(12):378-86.
10
Experience with bone marrow transplantation for severe aplastic anemia and leukemia. Two years experience with 31 patients in Zagreb (Yugoslavia).
Biomed Pharmacother. 1986;40(9):332-7.